Anabolic-androgenic Steroids : A Possible New Risk Factor of Toxicant-Associated Fatty Liver Disease

Anabolic-androgenic Steroids : A Possible New Risk Factor of Toxicant-Associated Fatty Liver Disease / Paulo Adriano Schwingel, Helma Pinchemel Cotrim, Bernardo Rios Salles, Carlos Eduardo Almeida, Crimério Ribeiro dos Santos Jr, Bruno Nachef, Antonio Ricardo Andrade, Cláudio Cesar Zoppi. - (Liver International 31 (2011) 3 (March); p. 348-353).

  • PMID: 21040407.
  • DOI: 10.1111/j.1478-3231.2010.02346.x


Background: Industrial toxin and drugs have been associated with non-alcoholic fatty liver disease (NAFLD); in these cases, the disease has been termed toxicant-associated steatohepatitis (TASH).

Aim: This study hypothesizes that the use of anabolic-androgenic steroids (AAS) could also be a risk factor to TASH or better toxicant-associated fatty liver disease (TAFLD) development.

Methodology: Case-control study including 180 non-competitive recreational male bodybuilders from August/2007 to March/2009. Ninety-five had a history of intramuscular AAS use (cases; G1) and 85 were non-users (controls; G2). They underwent a clinical evaluation and abdominal ultrasound, and their blood levels of aminotransferases, creatine phosphokinase (CPK), lipids, glucose and insulin were measured. TAFLD criteria: history of AAS use >2 years; presence of hepatic steatosis on ultrasound and/or aminotransferase alterations with normal CPK levels; exclusion of ethanol intake ≥20 g/day or use of other drugs; and exclusion of obesity, dyslipidaemia, diabetes and other liver diseases. Homeostasis model assessment for insulin resistance ≥3 was considered insulin resistant. Independent t-test, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.

Results: All cases were asymptomatic. Clinical and laboratorial data were similar in G1 and G2 (P>0.05). TAFLD criteria were observed in 12.6% of the G1 cases and 2.4% of controls had criteria compliant with non-alcoholic fatty liver related to metabolic conditions. OR was 6.0 (95% CI: 1.3-27.6).

Conclusions: These results suggest that AAS could be a possible new risk factor for TAFLD. In this type of fatty liver disease, the individuals had a low body fat mass and they did not present insulin resistance.


Research / Study
11 October 2010
Almeida, Carlos Eduardo
Andrade, Antônio Ricardo Cardia Ferraz de
Cotrim, Helma Pinchemel
Nachef, Bruno
Salles, Bernardo Rios
Santos, Crimério Ribeiro dos
Schwingel, Paulo Adriano
Zoppi, Cláudio Cesar
Other organisations
Universidade Federal da Bahia (UFBA) - Federal University of Bahia
Doping classes
S1. Anabolic Agents
Medical terms
Health effects
Kidney / liver disease
Document category
Date generated
3 June 2020
Date of last modification
1 December 2021
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period